Brokerages forecast that Krystal Biotech Inc (NASDAQ:KRYS) will report ($0.22) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Krystal Biotech’s earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.20). The company is scheduled to report its next quarterly earnings report on Monday, March 11th.
According to Zacks, analysts expect that Krystal Biotech will report full year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($1.13) to ($0.88). For the next year, analysts expect that the business will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.54) to ($0.96). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Krystal Biotech.
Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 5th. The company reported ($0.26) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.26).
KRYS has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 target price on shares of Krystal Biotech in a report on Monday, October 15th. Zacks Investment Research lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, October 6th. HC Wainwright upped their target price on shares of Krystal Biotech from $32.00 to $35.50 and gave the stock a “buy” rating in a report on Monday, October 15th. ValuEngine upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Friday, September 21st. Finally, William Blair reiterated a “buy” rating on shares of Krystal Biotech in a research note on Monday, November 5th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Krystal Biotech has an average rating of “Buy” and a consensus price target of $32.60.
In other news, insider Krish S. Krishnan acquired 25,000 shares of the firm’s stock in a transaction on Thursday, October 18th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 45.80% of the company’s stock.
Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC increased its stake in Krystal Biotech by 552.2% in the 2nd quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock valued at $182,000 after buying an additional 10,331 shares during the last quarter. BlackRock Inc. increased its stake in Krystal Biotech by 75.4% in the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock valued at $194,000 after buying an additional 5,607 shares during the last quarter. P.A.W. Capital Corp bought a new position in shares of Krystal Biotech during the 3rd quarter valued at approximately $527,000. JPMorgan Chase & Co. grew its position in shares of Krystal Biotech by 69.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock valued at $635,000 after acquiring an additional 14,755 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Krystal Biotech during the 3rd quarter valued at approximately $891,000. Hedge funds and other institutional investors own 18.83% of the company’s stock.
Shares of KRYS traded up $0.02 on Friday, reaching $23.49. The company’s stock had a trading volume of 52,664 shares, compared to its average volume of 51,470. Krystal Biotech has a twelve month low of $8.03 and a twelve month high of $28.75. The firm has a market capitalization of $338.65 million, a PE ratio of -15.87 and a beta of -0.66.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Story: What are the risks of holding treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.